Olanzapine: A potent agonist at the hM4D(Gi) DREADD amenable to clinical translation of chemogenetics. (2019)

First Author: Weston M
Attributed to:  Gene therapy for refractory epilepsy funded by MRC


No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1126/sciadv.aaw1567

PubMed Identifier: 31001591

Publication URI: http://europepmc.org/abstract/MED/31001591

Type: Journal Article/Review

Volume: 5

Parent Publication: Science advances

Issue: 4

ISSN: 2375-2548